¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"lymphocyte activation"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
12
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
lymphocyte activating factor
¸²ÇÁ±¸È°¼ºÀÎÀÚ
lymphocyte inhibitory factor
¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
lymphocyte series
¸²ÇÁ±¸°è¿
lymphocyte-activating determinant
¸²ÇÁ±¸È°¼º°áÁ¤ÀÎÀÚ
mixed lymphocyte culture
È¥ÇÕ¸²ÇÁ±¸¹è¾ç
mixed lymphocyte culture test
È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
mixed lymphocyte reaction
¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
monocyte lymphocyte ratio
´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
primed lymphocyte
ÃÊȸ¹Î°¨¸²ÇÁ±¸
primed lymphocyte typing
ÃÊȸ¹Î°¨¸²ÇÁ±¸Çü°áÁ¤
reticular lymphocyte
±×¹°¸²ÇÁ±¸, ¸Á»ó¸²ÇÁ±¸
sensitized lymphocyte
¹Î°¨È¸²ÇÁ±¸
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
lymphocyte activating factor
¸²ÇÁ±¸È°¼ºÀÎÀÚ
lymphocyte inhibitory factor
¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
killer lymphocyte
¼¼Æ÷µ¶¼º¸²ÇÁ±¸
lymphocyte
¸²ÇÁ±¸
leukocytoid lymphocyte
¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
lymphocyte series
¸²ÇÁ±¸°è¿
primed lymphocyte
ÃÊȸ¹Î°¨¸²ÇÁ±¸
resident lymphocyte
»óÁÖ¸²ÇÁ±¸
reticular lymphocyte
¸Á»ó¸²ÇÁ±¸
sensitized lymphocyte
¹Î°¨¸²ÇÁ±¸
short lived lymphocyte
´Ü»ý¸²ÇÁ±¸, ªÀº¼ö¸í¸²ÇÁ±¸
thymic lymphocyte
°¡½¿»ù¸²ÇÁ±¸
thymus-derived lymphocyte
°¡½¿»ùÀ¯·¡¸²ÇÁ±¸
mixed lymphocyte reaction
¸²ÇÁ±¸È¥ÇÕ¹è¾ç¹ÝÀÀ
mixed lymphocyte culture test
È¥ÇÕ¸²ÇÁ±¸¹è¾ç°Ë»ç
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
polyclonal activation
´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
B cell/lymphocyte
B ¼¼Æ÷/¸²ÇÁ±¸
B lymphocyte
B ¸²ÇÁ±¸
B-lymphocyte
B ¸²ÇÁ±¸.
Bare lymphocyte syndrome
¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
T cell/lymphocyte
T ¼¼Æ÷/¸²ÇÁ±¸
T lymphocyte
T ¸²ÇÁ±¸
T-lymphocyte
T-Àӯı¸
anti-lymphocyte globulin
¸²ÇÁ±¸ Çױ۷κҸ°
antigen, lymphocyte defined (LD)
¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
granulocyte-monocyte-lymphocyte antigens
°ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
granulocyte-platelet-lymphocyte antigens
°ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
hodgkins disease,lymphocyte predominance
¸²ÇÁ±¸ ÇöÀúÇü
primed lymphocyte
ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
primed lymphocyte typing
ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
islet-activation factor
¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
macrophage,activation of
Ȱ¼ºÈ(üÀàõûù)
neutron activation analysis
Áß¼ºÀÚ¹æ»çȺм®(~Û¯ÞÒûùÝÂà°).
photochemical activation
±¤È°¼ºÈ(Ë´Ì· ËÛÌ´).
plasmin activation inhibitor
Çö󽺹ÎȰ¼ºÈ¾ïÁ¦Á¦(¡üÀàõûùåäð¤ð¥)
polyclonal B cell activation
B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
polyclonal activation
´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
sleep activation
¼ö¸éºÎȰ(¹ý)(¡Ý¥üÀÛö) ³úÆÄ(Òà÷î)ÀÇ .
thermal activation
¿È°¼ºÈ¹ÝÀÀ(æðüÀàõûù Úãëë).
tissue plasminogen activation
Á¶Á÷ ÇöóÁî¹Ì°Õ Ȱ¼º
tissue plasminogen activation inhibitor
Á¶Á÷ ÇöóÁî¹Ì³ë°Õ Ȱ¼º ¾ïÁ¦ÀÎÀÚ
trypsinogen activation peptide(TAP)
ventricular activation
½É½ÇÈïºÐ(ãýãøýéÝÇ).
ventricular activation
½É½ÇÈïºÐ(ãýãøýéÝÇ)
ventricular activation time
½É½ÇÈïºÐ½Ã°£(ãýãøýéÝÇãÁÊà).
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½